There is no cagrisema pill on the market today. Learn why the drug is still a weekly injection, what trials show, and which oral weight loss options exist.
No CagriSema pill exists today. CagriSema is an investigational weight loss and diabetes drug that is given as a once-weekly subcutaneous injection, and no oral tablet or capsule version has been approved by the FDA. Any product marketed online as a "CagriSema pill" is not the real drug.
What Is CagriSema?
CagriSema is Novo Nordisk's combination of two gut-hormone analogs in a single injection: cagrilintide, a long-acting amylin analog, and semaglutide, the GLP-1 receptor agonist used in Ozempic and Wegovy. Each component is dosed at 2.4 mg once weekly.
The two hormones lower appetite through different routes. Amylin slows stomach emptying and boosts fullness signals, while semaglutide acts on GLP-1 receptors in the brain and gut to reduce hunger and food intake.
CagriSema is not FDA-approved for any indication. It is available in the United States only to volunteers enrolled in clinical trials.
Why There Is No CagriSema Pill Yet
Peptides are fragile molecules. Stomach acid and digestive enzymes break them apart before they reach the bloodstream, and their size makes it hard to cross the intestinal wall intact.
Oral semaglutide (Rybelsus) solves this only partly. It uses a carrier molecule called SNAC to help a small fraction survive absorption, and bioavailability is still around 1%. That is why the tablet must be taken on an empty stomach with a strict waiting period before food or other drinks.
Building one tablet that delivers two peptides with different absorption profiles is harder still. Novo Nordisk has not announced an oral CagriSema development program, and its tablet work has centered on oral semaglutide instead.
CagriSema Trial Results So Far
The Phase 3 REDEFINE program is testing injectable CagriSema. Results reported to date include:
- REDEFINE 1 (adults with obesity or overweight, without diabetes): about 20.4% average weight loss at 68 weeks across all randomized participants, and roughly 22.7% among those who stayed on treatment.
- About 40% of REDEFINE 1 participants lost 25% or more of their body weight.
- REDEFINE 2 (adults with type 2 diabetes): about 15.7% average weight loss at 68 weeks.
- REDEFINE 3 is evaluating cardiovascular outcomes.
For context, semaglutide 2.4 mg alone produced about 14.9% weight loss in REDEFINE 1, and cagrilintide alone about 11.5%. No clinical trial has tested an oral version of CagriSema. Anyone reading a retatrutide vs cagrisema comparison should note that both drugs are investigational injections, not tablets.
Weight Loss Pills That Do Exist vs CagriSema
Several oral options are already approved in the US, though none of them contains cagrilintide.
| Option | Form | FDA status | Approved use |
|---|---|---|---|
| CagriSema | Once-weekly injection | Investigational | None — trials only |
| Oral Wegovy (semaglutide 25 mg) | Daily tablet | Approved | Chronic weight management |
| Rybelsus (oral semaglutide 3, 7, 14 mg) | Daily tablet | Approved | Type 2 diabetes |
| Phentermine/topiramate, naltrexone/bupropion | Daily tablets | Approved | Chronic weight management |
| Orforglipron | Daily tablet | Investigational | Trials in obesity and type 2 diabetes |
Oral Wegovy is the closest approved product to a "GLP-1 pill." In the OASIS 4 trial, wegovy pill weight loss results averaged about 13.6% at 64 weeks in adults with obesity or overweight who did not have diabetes. That is a meaningful result, but it is lower than the numbers reported for injectable CagriSema.
Safety and Side Effects
Because CagriSema contains semaglutide, it carries the same class warnings as other GLP-1 medications.
- Common effects: nausea, vomiting, diarrhea, constipation, and abdominal pain, especially during dose increases.
- Boxed warning: thyroid C-cell tumors seen in rodents. People with a personal or family history of medullary thyroid carcinoma or MEN2 should not use it.
- Less common but serious: pancreatitis, gallbladder disease, low blood sugar when combined with insulin or sulfonylureas, and kidney injury from dehydration.
- Not recommended during pregnancy; pregnancy should be planned after stopping the drug.
Gray-Market "CagriSema Pills" Are Not the Real Drug
Capsules sold as CagriSema are unapproved, unregulated, and rarely tested for identity or purity. The same problem runs across the peptide market — no aod 9604 pill form has been approved by the FDA for fat loss, either. Buyers have no way to confirm what is inside the capsule or how it was manufactured.
What to Do If You Want a Pill Instead of a Shot
A clinician can help you weigh approved tablets against injectables based on your health history and goals. Ask specifically about oral Wegovy, older combination tablets, and whether a GLP-1 medication is appropriate for you at all.
If you do start a tablet, your prescriber will follow a wegovy pill dosing chart that steps the dose up over several weeks to limit stomach side effects. Many telehealth sites explain how to get wegovy pill prescription online, but a legitimate service still requires a licensed clinician review and a pharmacy-dispensed prescription rather than a research-chemical website.
CagriSema may become an important injectable option, but a CagriSema pill is not something you can buy today, and it is not something the current evidence suggests is coming soon.
Frequently Asked Questions
Is CagriSema available as a pill?
No. CagriSema is an investigational once-weekly injection, and no oral version has been approved by the FDA or tested in late-stage clinical trials. Products sold online as CagriSema pills or capsules are not the approved drug and have not been verified for identity, purity, or dose.
When will CagriSema be approved in the US?
CagriSema is still in Phase 3 trials, and Novo Nordisk has said it plans to seek regulatory approval for the injectable form. The FDA has not approved it, and no timeline has been set for any approval. Even if the injection is approved, a CagriSema pill would need its own formulation and clinical trials.
What is the closest thing to a CagriSema pill available today?
Oral Wegovy, a daily semaglutide tablet approved for chronic weight management, is the closest approved option, and trial results showed roughly 13.6% average weight loss at 64 weeks. It contains only semaglutide, not cagrilintide, so it is not the same drug. A licensed clinician can advise on whether a tablet or an injection fits your situation.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.